Business

Pharmaxis has announced that beginning in June 2015, Chiesi Farmaceutici will take over the commercialization of the Bronchitol mannitol DPI for the treatment of cystic fibrosis in the UK, Ireland, and Germany. Additionally, Pharmaxis said that is ending its commercialization agreement with Quintiles, which was announced in 2011 and, for the time being, will … [Read more...] about Chiesi to commercialize Bronchitol in the UK, Ireland, and Germany

Actavis has announced that it is relaunching 0.25 and 0.5 mg vials of budesonide inhalation suspension, a generic version of AstraZeneca's Pulmicort Respules, after the United States Court of Appeals for the Federal Circuit lifted an injunction preventing Actavis from marketing the product. The court upheld a lower court's determination that US Patent No. 7,524,834, … [Read more...] about Appeals court confirms Pulmicort Respules patent invalid, Actavis re-launches its generic version

Pennsylvania-based Egalet Corporation has announced that it will begin promoting Sprix ketorolac tromethamine nasal spray in the second quarter of 2015. Sprix is a non-steroidal anti-inflammatory drug (NSAID) for the short-term treatment of moderate to moderately severe pain, which was acquired by Egalet from Daiichi Sankyo subsidiary Luitpold Pharmaceuticals earlier … [Read more...] about Egalet to begin promoting Sprix nasal spray

California-based InCarda Therapeutics (formerly Pleiades Cardio-Therapeutics) has announced that it raised over $5 million with the possibility of an additional $1.5 million in a private financing round led by Morningside Venture. According to the company, it will use the proceeds for development of an inhaled therapy for paroxysmal atrial fibrillation. InCarda … [Read more...] about InCarda raises more than $5 million for development of inhaled cardiac drugs

According to Mylan, the United States Court of Appeals for the Federal Circuit has affirmed a lower court's March 2014 decision upholding the validity of four Mylan patents related to Perforomist formoterol fumarate inhalation solution and infringement of the patents by Teva. The patents (Nos. 6,667,344; 6,814,953; 7,348,362; and 7,462,645) protect Perforomist … [Read more...] about Court of Appeals upholds Mylan Perforomist patents

AstraZeneca announced that it has entered into a five-year partnership agreement with patient network PatientsLikeMe for access to patient-reported data in several treatment areas, including respiratory. PatientsLikeMe offers a program called "data for good," whose slogan is "donate your data for you, for others, for good." On its website, the company informs … [Read more...] about AstraZeneca partners with PatientsLikeMe

CDMO Molecular Profiles has announced that the company has a new name: Juniper Pharma Services. The company, whose services include formulation development and clinical trial manufacturing of dry powder inhalers, was acquired in 2013 by US-based Columbia Laboratories, now called Juniper Pharmaceuticals. In April 2014, Molecular Profiles announced that it planned to … [Read more...] about Molecular Profiles changes name to Juniper Pharma Services

Vectura has announced that it will close the former Activaero nebulizer manufacturing site in Gemünden, Germany by March 2016, transfering many of the site's operations to other Vectura facilities in Germany and the UK. Commercial production will be transferred to a contract manufacturing organization. Vectura acquired the Gemünden site when it acquired Activaero in … [Read more...] about Vectura to close former Activaero site in Gemünden

The European Patent Office has granted Evoke Pharma patent no. 2376075 for its EVK-001 intranasal metoclopramide for the treatment of diabetic gastroparesis symptoms in women, the company said. Earlier this year, Evoke announced that Phase 3 development of EVK-001 has been delayed by slower than expected enrollment in an ongoing clinical trial. Evoke President and … [Read more...] about Evoke Pharma’s intranasal metoclopramide formulations get European patent

Aptar Pharma has announced that a new budesonide DPI launched in China by Shanghai Sine Promod Pharmaceutical is the first marketed product to incorporate Aptar's new Twister device. The new 200µg dose budesonide inhaler is available in 30 capsule and 60 capsule versions for the treatment of asthma. In April 2012, Aptar Pharma announced the availability of the … [Read more...] about Shanghai Sine Promod Budesonide DPI incorporates Aptar’s Twister device